Silo pharma announces positive initial pharmacokinetic, safety, and tolerability study of sp-26 for chronic pain and fibromyalgia

No serious side effects or discomfort observed final safety and absorption data expected in march 2025 sarasota, fl, feb. 11, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced a positive update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel sp-26 ketamine extended-release rods when implanted subcutaneously. the sp-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia.
SILO Ratings Summary
SILO Quant Ranking